Dr. Tammuella Chrisentery-Singleton Joins ATHN as Chief Science Officer
ROCHESTER, NY – March 8, 2023 - The American Thrombosis and Hemostasis Network (ATHN) is pleased to announce that Tammuella Chrisentery-Singleton, MD is joining ATHN as its Chief Science Officer. Dr. Singleton will join ATHN’s executive leadership team in early May and will lead ATHN’s science and research strategy, while providing operational guidance to ATHN’s research department.
“ATHN aims to leverage our extensive informatics and research infrastructure to support exploration of pressing clinical and scientific questions, with the ultimate goal of improving the health and well-being of persons with rare disorders,” said Crystal Watson, ATHN President and CEO. “We look forward to working with Dr. Singleton as she applies her extensive clinical and research expertise to maximize the impact of ATHN research.”
Dr. Singleton is a nationally respected leader in pediatric hematology and an experienced provider for children, adolescents and adults living with bleeding, clotting and other rare blood disorders. She is board-certified in general pediatrics and pediatric hematology/oncology. She completed her pediatric residency training and pediatric hematology/oncology training at The University of Miami School of Medicine and The Johns Hopkins University School of Medicine/National Cancer Institute.
Dr. Singleton most recently served as the Chief of Pediatric Hematology and Director of the Hemophilia Treatment Center for the Mississippi Center for Advanced Medicine. She previously served as the Chief of Pediatric Hematology and Oncology, the Director of the Sickle Cell Center of South Louisiana, and the Associate Director of the Louisiana Center for Bleeding and Clotting Disorders at the Tulane University School of Medicine / Tulane Hospital for Children. Dr. Singleton currently serves as the principal investigator for ATHN 16: Safety of SEVENFACT® for the Treatment of Bleeding Events in Patients with Hemophilia A or B with Inhibitor and has led 60+ studies during her career.
“I’ve enjoyed partnering with ATHN to advance research for bleeding disorders, and I’m honored to be selected to steer the organization’s research strategy,” said Dr. Singleton. “There are many clinical questions that have yet to be answered, and I look forward to collaborating with investigators across the country to drive research that moves the needle forward on patient care.”
The American Thrombosis and Hemostasis Network (ATHN) is a non-profit, 501(c)3 whose mission is improving the health and well-being for individuals with rare disorders. ATHN provides a national informatics platform and partners with 150 ATHN-affiliated blood disorder treatments centers, government programs, community-based organizations, and industry partners to conduct research, public health surveillance, and quality improvement initiatives that support clinical care and outcomes analysis.